Creative Biolabs shares an outlook on the use of bacteriophages as a Tuberculosis diagnostic tool for the detection of TB infection.
Developments surrounding phage therapy in Australia have been approved to regulate the process of phage therapy, rather than a specific phage product.
ACD Pharma, a Norwegian research and development company, is constructing the first world’s large-scale phage production plant.
Creative Biolabs shares research on unmodified bacteriophages against Shigella flexneri, focusing on the use of natural phages to treat dysentery.
Anna Dragoš receives funding from the European Research Council (ERC) for the project PHAGECONTROL – The evolution of host manipulation by bacteriophage.
The battle against SARS-CoV-2 has presented the potential for the use of phage therapy for Covid19 rehabilitation of post-Covid19 patients.
TechnoPhage announces the first Clinical Safety results of the Innovative Biological product TP-102 against diabetic foot infections (DFI).
Creative Biolabs accumulated extensive experience in the development of various updated phage engineering techniques.
Many new and highly diverse bacteriophages; Flavophages have been discovered by researchers from the Max Plank Institute for Marine Microbiology, that impact the North Sea bacterial community and carbon cycle of the habitat.